The U.S. Food and Drug Administration (FDA) has approved five symptomatic drugs for the treatment of AD, including three cholinesterase inhibitors (rivastigmine, galantamine, donepezil) and memantine and memantine mixed with donepezil (Alzheimer’s Association, 2019). The gene discussed is BCHE; the disease is Alzheimer disease.